Logo
Paradigm Biopharmaceuticals

Respiratory Diseases

Acute respiratory distress syndrome and allergic rhinitis are inflammatory conditions of the lungs and airways with few disease-modifying options. Paradigm’s respiratory work is exploratory: the ARDS research is preclinical, in a mouse model, and the allergic rhinitis programme completed a Phase 2a trial in 2017 that did not meet its primary clinical endpoints.

The programmes

Paradigm’s respiratory work covers two indications, and they sit at very different points. The acute respiratory distress syndrome (ARDS) work is preclinical: a single translational study in a mouse model of influenza A infection, run with the Menzies Health Institute Queensland at Griffith University and published in 2023. There is no ARDS clinical trial.

The allergic rhinitis (AR) programme reached human testing. An intranasal PPS spray completed a Phase 1 study and then a Paradigm-sponsored Phase 2a trial in Sweden, which did not meet its primary clinical endpoints. Neither indication has a trial open or planned.

ARDS · Acute respiratory distress syndrome

Status
Preclinical. Proof of concept in mice; no clinical trial has been conducted
Model
Immunocompetent C57BL/6J mice, infected intranasally with a sublethal dose of influenza A virus, strain A/Puerto Rico/8/1934
Collaboration
Menzies Health Institute Queensland, Griffith University
Publication
Frontiers in Immunology, 9 February 2023 · doi:10.3389/fimmu.2023.1030879

AR · Allergic rhinitis (hay fever)

Status
Complete. Paradigm reported in May 2017 that the Phase 2a trial did not meet its primary clinical endpoints
Route
Intranasal PPS spray
Design
Phase 2a randomised, double-blind, placebo-controlled cross-over allergen challenge; 80 participants
Site
Skåne University Hospital, Lund, Sweden

Milestones

Every date below comes from Paradigm’s own disclosures or from the published literature. No respiratory milestone is currently guided: the allergic rhinitis programme ended at Phase 2a in 2017, and the ARDS work remains preclinical.

  1. Mar 2017 Final participant treated in the Phase 2a allergic rhinitis trial, Lund, Sweden Complete
  2. May 2017 Paradigm reported that the Phase 2a allergic rhinitis trial did not meet its primary clinical endpoints Complete
  3. Feb 2023 Preclinical ARDS study in mice published in Frontiers in Immunology Complete

Key ARDS figures

These figures describe acute respiratory distress syndrome only. They come from LUNG SAFE, an international observational study of intensive care units in 50 countries.

ICU incidence 10.4% Of all ICU admissions ARDS represented 10.4% of intensive care unit admissions (95% CI 10.0–10.7).
Ventilated patients 23.4% Of ventilated patients ARDS accounted for 23.4% of all patients requiring mechanical ventilation (95% CI 21.7–25.2).
Mortality 40.0% Hospital mortality Overall in-hospital mortality for patients with ARDS (95% CI 38.1–42.1).

Source: Bellani G, Laffey JG, Pham T, et al. Epidemiology, patterns of care, and mortality for patients with acute respiratory distress syndrome in intensive care units in 50 countries. JAMA. 2016;315(8):788–800. doi:10.1001/jama.2016.0291

Where to go next

If you or someone you care for is living with a respiratory condition, please note that Paradigm has no clinical trial open in acute respiratory distress syndrome or allergic rhinitis. The ARDS research is preclinical laboratory work in mice, and the allergic rhinitis trial in Sweden closed in 2017. Paradigm is unable to discuss individual eligibility for clinical trials or any matters relating to your condition — your own doctor is the right person to talk to about your treatment.

For investors, respiratory remains an exploratory part of the pipeline. Any change to its status would be announced to the ASX.

Pentosan polysulfate sodium is an investigational medicine in respiratory disease. It is not approved and is not available for the treatment of acute respiratory distress syndrome or allergic rhinitis in any market.